Image Analysis Group

What a proud moment, as Image Analysis Group gets recognized as the top businesses across the UK

'If you aim to disrupt an industry, you must be willing to disrupt yourself,' HBR line, timely for the fast changing world disrupted by the .

It is the job of the to embrace technology, empower your teams and maximize your chances of success when it comes to developing novel .

Understnding what technology can do for your company and how, will ensure transparency of information and success in the new normal of remote connectivity.

Today's era of bio-pharmaceutical R&D requires leaders who are not afraid to think and engage globally, who will expose themselves and their teams to this new digital era thinking and find partners to support them, IAG, IMAGE ANALYSIS GROUP

Read more and of course join us live on 21st May: https://www.ia-grp.com/news/webinar-ai-and-cloud/

If you aim to disrupt an industry, you must be willing to disrupt yourself Technology is an essential enabler for almost everything a biotech or pharma does in clinical trials: innovation, product management, operations. While in the past, company leaders may have not needed an in-depth understanding of technology challenges and opportunities, covid made us realize that th

is the day to recognize and those who helped them on their path! Join us, in a live webinar, talking about female leadership, on the 12 March 2021!

This is one day, when we talk about being a woman in the workspace, with our unique perspective on life and business. We want to share 4 journeys of , Image Analysis Group female technology leaders and hope this honest conversation can support and inspire.

Audience questions are as important as speakers’ notes! Join us, help us to drive this discussion.

Following the live session, we will openly share this webinar with anyone to draw from our take on being a female in technology and science!

Friday, 12th March, 2021, 1pm ET
Register here: https://lnkd.in/d2XBqHe

'Speak to the IT Girls', with Dr. Olga Kubassova, Dr. Diana Dupont-Roettger, IAG’s Chief Scientific Alliance Officer, Julia O'Lynn, IAG’s Imaging Specialist and Technologist, and Romiesa Hagoug, IAG’s Sn Project Manager.

Speak to the IT Girls! Live discussion with IAG’s female technology leaders: sharing our story, career journey and aspirations!

Link: https://www.ia-grp.com/views/biotech-and-tech-2021/

Opinion piece on what to expect in 2021 - huge IT challenges or the Right Solutions coming in the right time? Will this be the year to reward those who are breaking the mould and pushing adaptation of innovation across the therapeutic areas.

This piece is focused on a few technology solutions, which can make a real difference in biotech / pharma drug development and help the sector can prevail over covid:

, technologies that support while
enabling data sharing, , , and for acceleration and decision making.

Data Privacy and Data Exchange
Vaccine Passports
Drug Development for Diseases other the Covid
AI: from Computer-Aided Assessments to Radiomics
From Telehealth to Objective Metrics of Drug Performance.

with IAG, IMAGE ANALYSIS GROUP

https://www.linkedin.com/pulse/biotech-tech-2021-dr-olga-kubassova

Biotech and Tech: 2021+ We are out of the 2020, and into 2021, reminiscing of the first lockdowns and re-analysing the biotech sector rise. On our minds, probably daily – is the vaccine challenge, especially as both Pfizer and AstraZeneca are warning about the vaccine shortages.

business mentions , Image Analysis Group partnership with CNS pharma focused on the development on their novel drug.

Full press release: http://www.ia-grp.com/news/cns_berubicin_partnership/

The new normal is here: era of digital R&D, , and supporting accelerated drug development and virtual reality of today's and lives!

It’s a wonderful life! As I am working through my notes to talk at the European Biotech week virtual meeting, a lot comes to mind. 2020 has been a challenging year for biotechnology companies and investors, no doubt.

Our latest article: Emerging trends in bringing novel technologies, advanced and – learnings from

http://www.ia-grp.com/views/chinabio-iag/

Uncertainties & Opportunities: BioPharma in the Era of Covid19 Bio-Pharma Crisis & Opportunities in the Era of Covid As Crunchbase reports that ‘in 2009, one-third fewer start-ups raised early-stage funding,’ we already see investors advising biotechs to plan for two years without raising new funding. Is this the right advice in today’s situation? Should ...